A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease

Treatment beyond progressive disease (PD) is a concept that even after drugs become ineffective, their continued use is more beneficial for patients than their discontinuation. In recent years, a concept of bevacizumab beyond PD (BBP) has attracted attention in the treatment of various cancers, and...

Full description

Bibliographic Details
Main Authors: Tadahiro Shoji, Hisashi Eto, Takanori Sato, Rikako Soma, Daisuke Fukagawa, Hidetoshi Tomabechi, Eriko Takatori, Takayuki Nagasawa, Seiya Sato, Masahiro Kagabu, Tsukasa Baba
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Healthcare
Subjects:
recurrent ovarian cancer
chemotherapy
bevacizumab beyond PD
MITO16/MaNGO-OV2B
JGOG3023
Online Access:https://www.mdpi.com/2227-9032/7/3/109

Internet

https://www.mdpi.com/2227-9032/7/3/109

Similar Items